Creatine phosphokinase elevation exacerbated by levetiracetam therapy

A 19-year-old muscular male with a history of epilepsy presented following two convulsive events. Levetiracetam (LEV) was given as an additional therapy, resulting in a marked boost in creatine phosphokinase (CPK) that could not easily be explained by renal dysfunction or rhabdomyolysis alone. Levet...

Full description

Bibliographic Details
Main Authors:	Julia E. Isaacson, Dongwhoon J. Choe, Michael J. Doherty
Format:	Article
Language:	English
Published:	Elsevier 2014-01-01
Series:	Epilepsy and Behavior Case Reports
Subjects:	Epilepsy Toxicity Rhabdomyolysis Renal Sarcolemma Muscle
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213323214000504

id	doaj-9e595d9a549542e297915ce970f78a2c
record_format	Article
spelling	doaj-9e595d9a549542e297915ce970f78a2c2020-11-24T22:38:44ZengElsevierEpilepsy and Behavior Case Reports2213-32322014-01-012C18919110.1016/j.ebcr.2014.09.008Creatine phosphokinase elevation exacerbated by levetiracetam therapyJulia E. Isaacson0Dongwhoon J. Choe1Michael J. Doherty2Dartmouth College, Department of Psychological & Brain Sciences, Maynard Street, Hanover, NH 03755, USAUniversity of Washington, School of Public Health, 1959 NE Pacific Street, Seattle, WA 98195, USASwedish Epilepsy Center, 550 17th Avenue, Seattle, WA 98122, USAA 19-year-old muscular male with a history of epilepsy presented following two convulsive events. Levetiracetam (LEV) was given as an additional therapy, resulting in a marked boost in creatine phosphokinase (CPK) that could not easily be explained by renal dysfunction or rhabdomyolysis alone. Levetiracetam discontinuation caused CPK levels to quickly normalize and should be considered in patients with persisting CPK elevations postconvulsive seizure.http://www.sciencedirect.com/science/article/pii/S2213323214000504EpilepsyToxicityRhabdomyolysisRenalSarcolemmaMuscle
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Julia E. Isaacson Dongwhoon J. Choe Michael J. Doherty
spellingShingle	Julia E. Isaacson Dongwhoon J. Choe Michael J. Doherty Creatine phosphokinase elevation exacerbated by levetiracetam therapy Epilepsy and Behavior Case Reports Epilepsy Toxicity Rhabdomyolysis Renal Sarcolemma Muscle
author_facet	Julia E. Isaacson Dongwhoon J. Choe Michael J. Doherty
author_sort	Julia E. Isaacson
title	Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_short	Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_full	Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_fullStr	Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_full_unstemmed	Creatine phosphokinase elevation exacerbated by levetiracetam therapy
title_sort	creatine phosphokinase elevation exacerbated by levetiracetam therapy
publisher	Elsevier
series	Epilepsy and Behavior Case Reports
issn	2213-3232
publishDate	2014-01-01
description	A 19-year-old muscular male with a history of epilepsy presented following two convulsive events. Levetiracetam (LEV) was given as an additional therapy, resulting in a marked boost in creatine phosphokinase (CPK) that could not easily be explained by renal dysfunction or rhabdomyolysis alone. Levetiracetam discontinuation caused CPK levels to quickly normalize and should be considered in patients with persisting CPK elevations postconvulsive seizure.
topic	Epilepsy Toxicity Rhabdomyolysis Renal Sarcolemma Muscle
url	http://www.sciencedirect.com/science/article/pii/S2213323214000504
work_keys_str_mv	AT juliaeisaacson creatinephosphokinaseelevationexacerbatedbylevetiracetamtherapy AT dongwhoonjchoe creatinephosphokinaseelevationexacerbatedbylevetiracetamtherapy AT michaeljdoherty creatinephosphokinaseelevationexacerbatedbylevetiracetamtherapy
_version_	1725712172477054976

Creatine phosphokinase elevation exacerbated by levetiracetam therapy

Similar Items